CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression

Escitalopram (ESC), a selective serotonin reuptake inhibitor indicated for the treatment of depression and anxiety disorders, is primarily metabolized by cytochrome P450 (CYP) 2C19, which is a highly polymorphic enzyme known to cause inter-individual differences in pharmacokinetics. We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernini de Brito, Rodrigo, Ghedini, Paulo César
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264488/
https://www.ncbi.nlm.nih.gov/pubmed/32509985
http://dx.doi.org/10.1016/j.heliyon.2020.e04015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264488/
https://www.ncbi.nlm.nih.gov/pubmed/32509985
http://dx.doi.org/10.1016/j.heliyon.2020.e04015

Ejemplares similares